About me
Joshua Reuss, MD, is a thoracic medical oncologist at MedStar Georgetown University Hospital. He also serves as an assistant professor in the Department of Medicine at Georgetown University Medical Center.
Dr. Reuss specializes in lung cancer, mesothelioma, and thymoma. His research focuses on incorporating novel concepts and groundbreaking science to develop innovative clinical trials that advance the care of patients with lung cancer and mesothelioma. He has a particular interest in collaborating with scientific investigators to develop studies that help improve our understanding of the response and resistance mechanisms to immunotherapy in lung cancer and mesothelioma, as well as to develop trials that incorporate novel therapies that overcome immunotherapy resistance. He received the Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology in 2019 for his research.
Dr. Reuss earned his bachelor’s degree in biology at Brandeis University and his MD from the University of Rochester School of Medicine & Dentistry. He completed his internship and residency in Internal Medicine at the University of Virginia’s Department of Medicine. He subsequently completed a fellowship in the Department of Oncology at the Johns Hopkins University School of Medicine.
MedStar Georgetown is part of the MedStar Georgetown Cancer Institute, which combines medical expertise, the latest therapies, and research across MedStar Health. Our research engine, the Georgetown Lombardi Comprehensive Cancer Center, is the only National Cancer Institute-designated comprehensive cancer center in the Washington, D.C., region. This partnership means we provide access to cutting-edge clinical trials and the latest breakthroughs in cancer care.
Clinical areas of focus
- Adenocarcinoma Of Lung
- Lung Cancer
- Lung Metastasis
- Mesothelioma
- Non Small Cell Lung Cancer
- Pulmonary Nodule
- Small Cell Lung Cancer
- Thymoma
- Thymus Cancer
Conditions and procedures
Conditions I treat
- Adenocarcinoma Of Lung
- Alk Translocation
- Asbestos Lung
- Chest Wall Tumors
- Egfr Mutation
- Inherited Lung Cancer Risk
- Kras Mutation
- Large Cell Cancer Of The Lung
- Lung Cancer
- Lung Metastasis
- Mediastinum Cancer
- Mesothelioma
- Non Small Cell Lung Cancer
- Pleural Cancer
- Pulmonary Carcinoid
- Pulmonary Nodule
- Ros1 Fusion
- Small Cell Lung Cancer
- Squamous Cancer Of The Lung
- Thoracic Malignancy
- Thymoma
- Thymus Cancer
Procedures I perform
- Cancer Immunotherapy
- Lung Cancer Genomics
Practice locations
Distance from Change LocationEnter your Location
3800 Reservoir Road Northwest Lombardi Cancer Center Washington, DC, 20007
202-444-2223Fax 202-444-1229
Insurance
MedStar Health accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Health, please call your insurance company.
-
List of insurance plans we accept
- Kaiser Permanente Medicare Advantage Signature and Select (aka Senior Advantage)
- Blue Choice Advantage & Healthy Blue (HMO, POS)
- UnitedHealthcare and AARP Medicare Complete Plans/ UHC Group Medicare Advantage Plans HMO, POS, PPO
- United Healthcare Options (PPO) (includes Empire PPO, GEHA, Compass Rose)
- Kaiser Permanente Signature-Added Choice
- UHC Community Plan of MD
- Medicare Fee for Service
- Kaiser MD Medicaid MCO
- Kaiser Permanente Signature
- Kaiser Virginia Premier
- Kaiser PermanenteSelect-Added Choice
- CFBCBS EPO
- Kaiser Permanente Flexible Choice POS
- UnitedHealthcare Medicare Adv/Special Needs Plans
- Private Health Care Systems (PHCS) (PPO)
- CFBCBS Federal Employee Program (Std/Basic PPO/Blue Focus)
- Kaiser Permanente Medicare Plus (Medicare Supplemental Plan)
- Kaiser Permanente Select
- Aetna Innovations: HMO & EPO Plus
- Select HMO/HealthFund/Health Network
- Aetna HMO
- Open POS II
- Innovation Health: Open POS Plus
- Choice POS & Choice POS II
- Aetna Managed Choice Open Access (POS)
- Open EPO Plus
- Opoen HMO Option
- Open HMO
- Innovation Health: POS
- Aetna HMO-Open Access/Select OA/HealthFund/Health Network Option OA
- Innovation Health: Open Network Only Plus
- Aetna Elect Choice/ Open Access (POS)
- Innovation Health: POS Plus
- Aetna Managed Choice (POS)
- Innovation Health: PPO
- Aetna Open Choice (PPO)
- Innovation Health: Indemnity
- Aetna Traditional Choice (PPO)
- BlueChoice Open Access
- CFBCBS Blue Choice Opt Out Open Access
- HealthyBlue PPO
- CFBSBC Blue Preferred PPO
- Choice Fund PPO
- PPO and PPO Plus
- CIGNA EPO
- POS OA & OA Plus
- Network OA
- CIGNA HMO Open Access (OA)
- United Healthcare Choice
- FIRST HEALTH
- Coventry of Delaware HMO/PPO
- Tricare for Life (Medicare Supplemental Plan)
- M.D. IPA Preferred (POS)
- CFBCBS Maryland Point of Service Plan (MPOS)
- United Healthcare Choice Plus
- United Healthcare Select Plus (POS)
- Aetna Worker's Compensation Network
- MedStar Family Choice - Maryland Health Choice
- United Healthcare Select HMO - EPO/NPP
- CFBCBS BlueChoice HMO
- First Health PPO
- Aetna Elect Choice/ EPO (Aetna Health Fund) Innovation Health: Network Only Plus
- Aetna Medicare Advantage HMO & PPO Plans
- CIGNA HMO & Network (HMO)
- Coventry Health Care National Network PPO
- CFBCBS (NCA) Indemnity
- Aetna Quality Point of Service (POS)
- Aetna Student Health Insurance
- CIGNA POS/Network POS
- Mamsi Life & Health (Indem./PPO)
- Optimum Choice Preferred (POS) & OCI Direct (HMO)
- United Student Resources
- CFBCBS Blue Choice Opt Out Plus Open Access (POS)
- CFBCBS Maryland Indemnity or PPO
- Coventry Health Care of Virginia
- Tricare Prime
- Great-West Healthcare POS/CIGNA
- M.D. IPA (HMO)
- CIGNA Indemnity
- MedStar Select (MedStar Associates' Plan)
Videos
Education
Board Certification: American Board of Internal Medicine, Internal Medicine
Board Certification: American Board of Internal Medicine, Medical Oncology
Fellowship Program: Johns Hopkins University School of Medicine (2020)
Residency Program: University of Virginia Health System (2017)
Medical School: University of Rochester School of Medicine (2014)
Awards
- Research Award Recipient, 3rd Annual EGFR Resisters Research Summit, 2021
- Selected Participant, Journal of Clinical Oncology – Precision Oncology Trainee Reviewer Mentoring Program, 2022
- Selected Participant, FDA-ASCO Hematology and Oncology Fellows Day Workshop, 2019
- Young Investigator Award, Conquer Cancer Foundation of ASCO, 2019
- Visiting Fellow, Investigational Drug Branch - Cancer Therapy Evaluation Program of the NCI, 2019
- Best Fellows Abstract Oral Presentation, IASLC Targeted Therapies of Lung Cancer Meeting, 2019
- Selected Participant, ASCO/AACR Methods in Clinical Cancer Research Workshop, 2018
Hospital affiliations
News and publications
i. Original Research
- Reuss JE, Brigham E, Psoter KJ, Voong KR, Shankar B, Ettinger DS, Marrone KA, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, Hales RK, D’Alessio F, Danoff SK, Forde PM, Suresh K, Naidoo J. Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. JTO Clin Res Rep. 2021 October 01; 2(10):100220. doi: https://doi.org/10.1016/j.jtocrr.2021.100220.
- Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH-C, Mog BJ, Hou W, Justesen S, Blosser R, Tam A, Anagnostou V, Cottrell TR, Guo H, Chan HY, Singh D, Thapa S, Dykema AG, Burman P, Choudhury B, Aparicio L, Cheung LS, Lanis M, Belcaid Z, El Asmar M, Illei PB, Wang R, Meyers J, Schuebel K, Gupta A, Skaist A, Wheelan S, Naidoo J, Marrone KA, Brock M, Ha J, Bush EL, Park BJ, Bott M, Jones DR, Reuss JE, Velculescu VE, Chaft JE, Kinzler KW, Zhou S, Vogelstein B, Taube JM, Hellmann MD, Brahmer JR, Mergoub T, Forde PM, Yegnasubramanian S, Ji H, Pardoll DM, Smith KN. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021;596(7870):126-132. doi: 10.1038/s41586-021-03752-4. PubMed PMID: 34608287; PubMed Central PMCID: PMC8338555.
- Reuss JE, Stern D, Foster JC, Ramaswami R, Lurain K, Chen HX, Streicher H, Kem R, Little RF, Sharon E. Assessment of cancer therapy evaluation program advocacy and inclusion rates of people living with HIV in anti-programmed death ligand 1 clinical trials. JAMA Netw Open. 2020 Dec 1;3(12):e2027110. doi: 10.1001/jamanetworkopen.2020.27110. PubMed PMID: 33258905; PubMed Central PMCID: PMC7709086.
- #Rahma OE, #Reuss JE, Giobbie-Hurder A, Razavi G-SE, Abu-Shawer O, Mehra P, Gupta S, Simon R, Khleif SN. Early 3+3 trial dose-escalation phase I clinical trial design and suitability for immune checkpoint inhibitors. Clin Cancer Res. 2020 Oct 20;clincanres.2669.2020. doi: 10.1158/1078-0432.CCR-20-2669. PubMed PMID: 33082209. #contributed equally.
- Reuss JE, Anangostou V, Cottrell TR, Smith KN, Verde F, Zahurak M, Lanis M, Murray JC, Chan HY, McCarthy C, Wang D, White JR, Yang S, Battafarano R, Broderick S, Bush E, Brock M, Ha J, Jones DR, Merghoub T, Taube J, Velculescu VE, Rosner G, Illei P, Pardoll DM, Topalian SL, Naidoo J, Levy B, Hellmann MD, Brahmer JR, Chaft JE, Forde PM. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020 Sep;8(2):e001282. doi: 10.1136/jitc-2020-001282. PubMed PMID: 32929052; PubMed Central PMCID: PMC7488786.
- Naidoo J, Reuss JE, Suresh K, Feller-Kopman D, Forde PM, Steinke SM, Rock C, Johnson DB, Nishino M, Brahmer JR. Immune-related (IR)-pneumonitis during the COVID-19 pandemic: Multidisciplinary recommendations for diagnosis and management. J Immunother Cancer. 2020 Jun;8(1):e000984. doi: 10.1136/jitc-2020-000984. PubMed PMID: 32554619; PubMed Central PMCID: PMC7316105.
- Zhang J, Ji Z, Caushi JX, El Asmar M, Anagnostou V, Cottrell TR, Chan HY, Suri P, Guo H, Merghoub T, Chaft JE, Reuss JE, Tam AJ, Blosser RL, Abu-Akeel M, Sidhom JW, Zhao N, Ha JS, Jones DR, Marrone KA, Naidoo J, Gabrielson E, Taube JM, Velculescu VE, Brahmer JR, Housseau F, Hellmann MD, Forde PM, Pardoll DM, Ji H, Smith KN. Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Clin Cancer Res. 2020 Mar 15;26(6):1327-1337. doi: 10.1158/1078-0432.CCR-19-2931. PubMed PMID: 31754049; PubMed Central PMCID: PMC7073288.
- Anagnostou V, Niknafs N, Marrone K, Bruhm DC, White JR, Naidoo J, Hummelink K, Monkhorst K, Lalezari F, Lanis M, Rosner S, Reuss JE, Smith KN, Adleff V, Rodgers K, Belcaid Z, Rhymee L, Levy B, Feliciano J, Hann CL, Ettinger DS, Georgiades C, Verde F, Illei P, Li QK, Baras AS, Gabrielson E, Brock MV, Karchin R, Pardoll DM, Baylin SB, Brahmer JR, Scharpf RB, Forde PM, Velculescu VE. Mulitmodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nature Cancer. 2020 Jan 13;1:99-111. doi: 10.1038/s43018-019-0008-8. PubMed PMID: 32984843; PubMed Central PMCID: PMC7514475
- Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J. Immune-related adverse events requiring inpatient admission: spectrum of toxicity, treatment, and outcomes. J Oncol Pract. 2019 Sep;15(9):e825-e834. doi: 10.1200/JOP.18.00703. PubMed PMID: 31386608. PubMed Central PMCID: PMC6743220.
- Cavelti-Weder C, Shtessel M, Reuss JE, Jermendy A, Yamada T, Caballero F, Bonner-Weir S, Weir GC. Pancreatic duct ligation after almost complete beta-cell loss: Exocrine regeneration but no evidence of beta-cell regeneration. Endocrinology. 2013 May;154(12):4493-502. doi: 10.1210/en.2013-1463. PubMed PMID: 24029238; PubMed Central PMCID: PMC3836076.
ii. Reviews and Editorials
- Reuss JE, Gosa L, Liu SV. Antibody drug conjugates in lung cancer: State of the current therapeutic landscape and future developments. Clin Lung Ca. 2021 Jul;S1525-7304(21)00192-3. doi: 10.1016/j.cllc.2021.07.011. PubMed PMID: 34420859.
- *Reuss JE, *Forde PM. Immunotherapy for mesothelioma: rationale and new approaches. Clin Adv Hematol Oncol. 2020 Sep;18(9):562-572. PubMed PMID: 33006585.
- *Reuss JE, Suresh K, *Naidoo J. Checkpoint inhibitor pneumonitis: Mechanisms, characteristics, management strategies, and beyond. Curr Oncol Rep. 2020 May 16;22(6):56. doi: 10.1007/s11912-020-00920-z. PubMed PMID: 32415399.
- Jonna S, Reuss JE, Kim C, Liu SV. Oral chemotherapy for treatment of lung cancer. Front Oncol. 2020 Apr 28;10:793. doi: 10.3389/fonc.2020.00793. PubMed PMID: 32426292; PubMed Central PMCID: PMC7212352.
- Schenk KM, Reuss JE, Choquette K, Spira AI. A review of canakinumab and its therapeutic potential for non-small cell lung cancer. Anticancer Drugs. 2019 Oct;30(9):879-885. doi: 10.1097/CAD.0000000000000832. PubMed PMID: 31503012.
- #Rosner S, #Reuss JE, Forde PM. PD-1 Blockade in Early-Stage Lung Cancer. Annu Rev Med. 2019 Jan;70:425-35. doi: 10.1146/annurev-med-050217-025205. PubMed PMID: 30355264. #contributed equally.